On September 11 | BeiGene (BGNE.US) rose 5.59% to $208.75 before the market. According to the news, the official website of the Drug Evaluation Center (CDE) of the State Drug Administration recently announced that the clinical trial application for the new Class 1 drug BGB-58067 tablets declared by BeiGene has been accepted. According to public information, BGB-58067 is a PRMT5 inhibitor. It is a product under development for solid tumors in BeiGene. It is expected to enter clinical research in 2024. In addition, ESMO (European Society of Medical Oncology), one of the top three major oncology conferences receiving global attention, will be held from September 13 to September 17. A number of innovative pharmaceutical companies will announce their major results at the conference.
美股异动 | 多重利好加身 百济神州盘前涨超5%
US stocks unusual movement | Multiple bullish factors added, Beigene's pre-market rise exceeds 5%
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.